GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Effective Interest Rate on Debt %

Ocugen (Ocugen) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ocugen's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Ocugen's average total debt for the quarter that ended in Dec. 2023 was $6.71 Mil. Therefore, Ocugen's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.


Ocugen Effective Interest Rate on Debt % Historical Data

The historical data trend for Ocugen's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Effective Interest Rate on Debt % Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.66 37.00 2.73 - -

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocugen's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Ocugen's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Ocugen's Effective Interest Rate on Debt % falls into.



Ocugen Effective Interest Rate on Debt % Calculation

Ocugen's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (6.374+6.941)/ 2 )
=-1  *  0/6.6575
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=5.876 + 0.498
=6.374

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.367 + 0.574
=6.941

Ocugen's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  0/( (6.475+6.941)/ 2 )
=-1  *  0/6.708
=0.00 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.659 + 1.816
=6.475

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.367 + 0.574
=6.941

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Ocugen  (NAS:OCGN) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Ocugen Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Ocugen's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (Ocugen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Effective Interest Rate on Debt %
Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355